Our Review Summary
This story is a good example of what an independent expert’s perspective can bring to a piece.
Why This Matters
Stories about predictive tests for Alzheimer’s Disease may play with the emotions of affected families. This story appropriately evaluated evidence, so that the current state of this research – what it might mean and what it does not yet mean – was crystal clear.
Criteria
Not Satisfactory
No discussion of costs. Yes, we know that it’s too early to use this in clinical settings, but the story makes the case that this builds on research following patients for as long as 12 years. Any predictive test would hold appeal for many people – so cost ramifications are important to discuss even at this early stage. Both tests are available at the present time so that with a little bit of digging, the costs could have been provided.
Satisfactory
We’ll give the story a satisfactory grade for providing context for the projected benefits of the test:
“A new study suggests that biomarkers found in cerebrospinal fluid (fluid that surrounds the spinal cord and brain and acts as a protective cushion) could predict who would develop Alzheimer’s disease 90% of the time among patients with mild cognitive impairment, a condition characterized by measurable memory problems.
…
Knowing which patient with mild cognitive impairment patients may go on to develop Alzheimer’s is vital information for researchers, who are looking for treatments for the fatal brain disease. The current thinking is that interventions will be most effective when given to a patient as early as possible.”
But the story is quick to note that it’s too early to use this as a diagnostic tool in clinical settings.
Satisfactory
The story did make several stabs at touching on harms, reporting:
“Some of the participants, who were originally found to be stable with mild cognitive impairment after about five years, went on to develop Alzheimer’s disease during the longer follow-up. That suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer’s disease, researchers say.”
And it did end with this:
“As scientists gain more insight into predicting Alzheimer’s, aging adults may struggle with the question of whether they want to know their risk, especially since there’s still no cure. Some people want to enroll in clinical trials as soon as they start showing symptoms; others would rather be ignorant of their status since there is no cure.”
We think these could have been framed more clearly as potential harms, but we’ll give the story the benefit of the doubt on this one.
Satisfactory
The story did an adequate job explaining what the study found, what it might mean, but what it does not yet mean.
Satisfactory
There was no disease-mongering in the story. In fact, it explained that “not everyone with this condition is a good candidate for an Alzheimer’s trial.”
Satisfactory
One independent expert’s comments added needed perspective to the findings.
Satisfactory
That independent expert added this important reminder:
“What I tell people is: If they’re worried about their thinking abilities, that they should make an appointment with a neuropsychology or a neurologist to get an evaluation,” Brinkman says. “The way we diagnose Alzheimer’s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.”
Satisfactory
Again, the independent expert’s perspective was important:
“When these sorts of studies get published, Brickman and other doctors get phone calls from aging adults wondering whether they should be getting spinal taps to assess their risk. But it’s too early to use this as a diagnostic tool in clinical settings, says Brickman. Down the road, the “fantasy” is that asymptomatic people will be able to get a biomarker test to determine whether they’ll one day get Alzheimer’s, but that’s not possible right now, he adds.”
Satisfactory
The story was clear that:
- the new research builds on prior published research
- the new study is the longest clinical followup of people who begin with mild cognitive impairment
Satisfactory
It’s clear that the story did not rely solely or largely on a news release.
Total Score: 9 of 10 Satisfactory
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like